TABLE 4
FROM:
Use of arrays to investigate the contribution of ATP-binding cassette transporters to drug resistance in cancer chemotherapy and prediction of chemosensitivity
Jian-Ting Zhang
BACK TO ARTICLETable 4. Highlights of ABC transporters identified to have increased expression and potential contributions to drug resistance
| ABC transporters | Cell lines/samples | Drugs | Functional validationa | References |
|---|---|---|---|---|
| ABCA1 | Breast Clinical samples | 5-FU/Paclitaxel | 25 | |
| ABCA2 | ALL Samples | Yes | 35 | |
| HL60/Ar | Adriamycin | 24 | ||
| GLC4-MITO | Mitoxantrone | Yes | 42 | |
| ABCA3 | AML Samples | Yes | 33 | |
| ALL Samples | Yes | 35 | ||
| HT-29/ETP | Etoposide | 10 | ||
| K562/etop80 | Etoposide | 10 | ||
| ABCA4 | HL60/Ar | Adriamycin | 24 | |
| MCF7/AdVp3000 | Adriamycin | 40 | ||
| ABCA5 | MCF7/AdVp3000 | Adriamycin | 40 | |
| ABCA7 | CEM/Adr5000 | Adriamycin | 24 | |
| HL60/Ar | Adriamycin | 24 | ||
| ABCA12 | Breast Clinical samples | 5-FU/Paclitaxel | 25 | |
| ABCB1 | TRL1215 | Arsenic | Yes | 14, 15 |
| SKOV3TX | Paclitaxel | 19 | ||
| KF28TX | Paclitaxel | 20 | ||
| HCT-15/FK228 | FK228 | 21 | ||
| IGROV1/FK228 | FK228 | 21 | ||
| MCF7/FK228 | FK228 | 21 | ||
| K562/FK228 | FK228 | 21 | ||
| TC/ET | ET-743 | Yes | 22 | |
| CCRF-CEM/ADR5000 | Adriamycin | 24 | ||
| KB-8-5 | Colchicine | 30 | ||
| SK3/VP16 | VP-16 | 10 | ||
| KB-3-1 | NSC73306 | 36, 37 | ||
| ABCB2 | HKCI-DOX | Adriamycin | 23 | |
| HL60/Ar | Adriamycin | 24 | ||
| ABCB3 | CEM/ADR5000 | Adriamycin | 24 | |
| HL60/Ar | Adriamycin | 24 | ||
| ABCB4 | TRL1215 | Arsenic | 14, 15 | |
| TC/ET | ET-743 | 22 | ||
| ABCB6 | MCF7/AdVp1000b | Adriamycin | 24 | |
| A549/CPT | Camptothecin | 10 | ||
| Breast Clinical samples | 5-FU/Paclitaxel | 25 | ||
| ABCB8 | CEM/ADR5000 | Adriamycin | 24 | |
| T24/cDDP10 | Cisplatin | 10 | ||
| ABCB9 | HKCI-DOX | Adriamycin | 23 | |
| CEM/ADR5000 | Adriamycin | 24 | ||
| ABCB10 | MCF7/AdVp3000 | Adriamycin | 40 | |
| HT-29/CPT | Camptothecin | 10 | ||
| ABCB11 | A549/CPT | Camptothecin | 10 | |
| ABCC1 | TRL1215 | Arsenic | Yes | 14, 15 |
| HL60/AR | Adriamycin | 24 | ||
| HT-29/ETP | Etoposide | 10 | ||
| K562/etop20 | Etoposide | 10 | ||
| K562/etop80 | Etoposide | 10 | ||
| ABCC2 | RCO.1 | 9-nitro-camptothecin | 30 | |
| MCF7/AdVp3000 | Adriamycin | 40 | ||
| ABCC3 | MCF7/AdVp1000 | Adriamycin | 24 | |
| MCF7/AdVp3000 | Adriamycin | Yes | 40 | |
| ABCC4 | HL60/AR | Adriamycin | 24 | |
| KK47/cDDP10 | Cisplatin | 10 | ||
| ABCC5 | MCF7/AdVp1000 | Adriamycin | 24 | |
| MCF7/AdVp3000 | Adriamycin | 40 | ||
| Breast Clinical samples | 5-FU/Paclitaxel | 25 | ||
| ABCC6 | HL60/AR | Adriamycin | 24 | |
| ABCC8 | MCF7/AdVp3000 | Adriamycin | 40 | |
| ABCC9 | SK3/VP16 | VP-16 | 10 | |
| SK3/VP | VP-16 | 10 | ||
| ABCC11 | Breast Clinical samples | 5-FU/Paclitaxel | 25 | |
| ABCC13 | Breast Clinical samples | 5-FU/Paclitaxel | 25 | |
| ABCD3 | SK3/VP | VP-16 | 10 | |
| ABCD4 | HT-29/ADM | Adriamycin | 10 | |
| KK47/cDDP10 | Cisplatin | 10 | ||
| K562/etop80 | Etoposide | 10 | ||
| ABCE1 | CEM/ADR5000 | Adriamycin | 24 | |
| HT-29/CPT | Camptothecin | 10 | ||
| ABCF2 | CEM/ADR5000 | Adriamycin | 24 | |
| T24/cDDP10 | Cisplatin | 10 | ||
| ABCF3 | MCF7/AdVp1000 | Adriamycin | 24 | |
| ABCG1 | MCF7/AdVp1000 | Adriamycin | 24 | |
| ABCG2 | LY/NR2 | NB-506 | Yes | 17 |
| MCF7/AdVp1000 | Adriamycin | 24 | ||
| MCF7/AdVp3000 | Adriamycin | 40 |
a The functional validation was conducted following identification by array analyses to verify the functional role of the ABC transporter in resistance to corresponding drugs tested. Some ABC transporters have known roles in resistance to the corresponding drugs from prior studies, which are not counted as functional validation in this table.
b This cell line was also named as MCF7/CH1000 in the original publication.
